Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy

NCT00664027 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00664027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
May 31, 2009
Enrollment
80 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy